The present invention relates to novel triazolo[4,3-a]pyridine derivatives of Formula (I)wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 ("mGluR2"), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.本發明係關於新穎的式(I)三唑并[4,3-a]吡啶衍生物其中所有基團均如申請專利範圍中所定義。本發明化合物為代謝型麩胺酸受體第2亞型(「mGluR2」)之正向異位性調節劑，其適用於治療或預防與麩胺酸功能障礙相關之神經及精神病症及涉及代謝型受體mGluR2亞型之疾病。本發明亦係關於包含該等化合物之醫藥組合物、製備該等化合物及組合物之方法、及該等化合物用於預防或治療涉及mGluR2之神經及精神病症及疾病的用途。
